Plus Lenalidomide News Today : Breaking News, Live Updates &

National Institute for Health and Care Excellence gives green light to Darzalex® (daratumumab) with lenalidomide and dexamethasone for patients with n

Published: September 22, 2023

Daratumumab combination is recommended for use within the NHS in England and Wales for treating adults with newly diagnosed multiple myeloma where a stem cell transplant is unsuitableEligible patients throughout England and Wales can now access alternative combination treatment option which has been shown to delay d...

Source: pharmiweb.com

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Published: December 12, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...

Source: prnewswire.com

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

Published: December 5, 2022

05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...

Source: wallstreet-online.de

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Published: August 28, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...

Source: prnewswire.com

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release

Published: August 27, 2022

Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen Pharm

Source: wiredprnews.com

Plus Lenalidomide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Plus Lenalidomide Today - Breaking & Trending Today

National Institute for Health and Care Excellence gives green light to Darzalex® (daratumumab) with lenalidomide and dexamethasone for patients with n

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release

Plus Lenalidomide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Plus Lenalidomide Today - Breaking & Trending Today

National Institute for Health and Care Excellence gives green light to Darzalex&#xAE; (daratumumab) with lenalidomide and dexamethasone for patients with n

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX&#xAE; (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX&#xAE; (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX&#xAE; (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release

National Institute for Health and Care Excellence gives green light to Darzalex® (daratumumab) with lenalidomide and dexamethasone for patients with n

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release